These mechanistic insights underscore the potential of PARPs as master regulators that couple chromatin dynamics to tumor-promoting transcriptional networks, providing a strong therapeutic rationale for combining PARP inhibition with transcription- and/or chromatin-targeted therapies. This evidence concerns the gene PARP1 and neoplasm.